- 969.678
- +7.103+0.74%
T2 Biosystems Reiterates Guidance
Reiterated 2024 Financial OutlookThe Company continues to expect full year 2024 total sepsis product revenue of $10.0 million to $11.0 million, representing growth of 49% to 64%, compared to $6.7 mill
T2 Biosystems Q1 2024 GAAP EPS $(2.66) Misses $(2.27) Estimate, Sales $2.061M Beat $2.000M Estimate
T2 Biosystems (NASDAQ:TTOO) reported quarterly losses of $(2.66) per share which missed the analyst consensus estimate of $(2.27) by 17.18 percent. This is a 97.98 percent increase over losses of $(13
T2 Biosystems Announced Execution Of Territory Exclusive Distribution Agreement In Qatar; To Sell T2Dx Instruments, T2Bacteria Panel, T2Candida Panel And T2Resistance Panel Through Newly Appointed Distributor
T2 Biosystems Announced Execution Of Territory Exclusive Distribution Agreement In Qatar; To Sell T2Dx Instruments, T2Bacteria Panel, T2Candida Panel And T2Resistance Panel Through Newly Appointed Dis
Earnings Flash (TTOO) T2 BIOSYSTEMS Posts Q1 Revenue $2.1M
04:35 PM EDT, 05/06/2024 (MT Newswires) -- Earnings Flash (TTOO) T2 BIOSYSTEMS Posts Q1 Revenue $2.1M
T2 Biosystems Announces Commercial Expansion Through Middle East Distributor
T2 Biosystems 1Q Loss/Shr $2.66 >TTOO
T2 Biosystems 1Q Loss/Shr $2.66 >TTOO
T2 Biosystems 1Q Loss $13.5M >TTOO
T2 Biosystems 1Q Loss $13.5M >TTOO
Press Release: T2 Biosystems Announces First Quarter 2024 Financial Results
T2 Biosystems Announces First Quarter 2024 Financial Results Achieved double-digit growth in sepsis product revenue and reduced debt by approximately 80% compared to the prior year period LEXINGTON,
Press Release: T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan Into Equity
T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity Strengthens balance sheet by reducing total debt by approximately 80% over the past year Filed Pursua
Gilead Sciences Unusual Options Activity For May 06
Financial giants have made a conspicuous bearish move on Gilead Sciences. Our analysis of options history for Gilead Sciences (NASDAQ:GILD) revealed 13 unusual trades.Delving into the details, we foun
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
SECAUCUS, N.J., May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technolo
How Is The Market Feeling About Gilead Sciences?
Gilead Sciences's (NYSE:GILD) short percent of float has risen 4.62% since its last report. The company recently reported that it has 22.57 million shares sold short, which is 1.81% of all regular sha
Ttoo T2 Biosystems Files For Offering Of Up To 3.32M Shares Of Common Stock Along With Series B-1 and Series B-2 Common Warrants
Ttoo T2 Biosystems Files For Offering Of Up To 3.32M Shares Of Common Stock Along With Series B-1 and Series B-2 Common Warrants
Goldman's Top 50 Weak Balance Sheet Stocks
Goldman Sachs analysts listed 50 stocks constituents of their “weak balance sheet” basket.
Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More
16 Out of 24 Health Care Companies Beat Topline Numbers This Week- Earnings Scorecard
23 Most Profitable Stocks of the Last 12 Months
In this article, we discuss the 23 most profitable stocks of the last 12 months.
T2 Biosystems Q1 Earnings Preview
Buy Rating Justified by Chimerix's Upcoming Catalysts and Strong Financials